news
Baricitinib and remdesivir reduce time to recovery in COVID-19 patients
A clinical trial in hospitalised COVID-19 patients has demonstrated that baricitinib and remdesivir reduce time to recovery.
List view / Grid view
R&D
news
Cabozantinib reduces tumour burden in Phase II neurofibromatosis trial
Forty percent of neurofibromatosis type 1 patients enrolled in the trial had a >20 percent reduction in tumour burden with cabozantinib.
news
Biopharma industry commits to working with regulatory agencies on COVID-19 vaccines
A statement from biopharmaceutical industry groups has said they plan to work with regulatory agencies to gather data on COVID-19 vaccines.
news
COVID-19 antibody therapy shows promise in Phase II/III trial
CT-P59, a monoclonal antibody therapy for COVID-19, was found to be particularly effective at reducing recovery times in moderate COVID-19 patients aged 50 plus.
webinar
Comparing EMA and Health Canada CTA submission for Phase I trials to US FDA IND application
13 January 2021 | By Altasciences
Watch this webinar on-demand which presents an overview of a foreign health authority’s requirements for gaining approval to conduct an FIH clinical trial by comparing Health Canada and European Medicines Agency (EMA) Clinical Trial Authorisation (CTA) processes to that of the FDA IND submission.
news
European Commission approves dispersible tablets to treat paediatric HIV
Marketing authorisation in the EU has been given to Tivicay (dolutegravir) dispersible tablets to treat HIV in certain paediatric patients.
news
Phase III trial to study interferon beta therapy in COVID-19 patients initiated
Synairgen's interferon beta therapy is being studied as a potential COVID-19 treatment in a Phase III trial as the first patient is dosed.
whitepaper
Whitepaper: Turbocharging Raman measurements
This whitepaper describes the proprietary HyperFlux™ optical spectrometer designs developed by Tornado Spectral Systems.
news
First patient dosed with COVI-VAC, an intranasal COVID-19 vaccine candidate
The trial will assess the safety and immunogenicity of a single intranasal dose of COVI-VAC in 48 healthy volunteers in the UK.
news
CDMO awarded $850,000 contract for development of Acute Cannabinoid Overdose treatment
Under the contract, IRISYS LLC will develop a new, injectable formulation of drinabant that can rapidly and effectively reverse the symptoms of Acute Cannabinoid Overdose (ACO).
news
FDA approves Phase III trial of synthetic biological COVID-19 treatment
The international Phase III trial will evaluate whether a 14 day course of carrimycin can improve outcomes for COVID-19 patients with severe symptoms.
news
FDA monitoring impact of SARS-CoV-2 mutations
The FDA has alerted clinical laboratory staff and healthcare providers that it is monitoring the potential impact of SARS-CoV-2 mutations, including the UK variant.
![Vials labelled 'COVID-19 Vaccine Pfizer' [Giovanni Cancemi / Shutterstock.com].](https://www.europeanpharmaceuticalreview.com/wp-content/uploads/Pfizer-covid-19-vaccine-300x278.jpg)
![Vials labelled 'COVID-19 Vaccine Pfizer' [Giovanni Cancemi / Shutterstock.com].](https://www.europeanpharmaceuticalreview.com/wp-content/uploads/Pfizer-covid-19-vaccine-scaled-e1607955047519.jpg)
article
Pfizer-BioNTech COVID-19 vaccine is effective against new, highly transmissible COVID-19 strains, finds study
Research shows that the antibodies induced by the Pfizer-BioNTech COVID-19 vaccine can neutralise SARS-CoV-2 viruses with the N501Y mutation.
news
Risankizumab trials show higher clinical remission in patients with Crohn’s disease
Two Phase III trials have shown that two doses of risankizumab met the primary endpoints in patients with Crohn's disease.
news
First COVID-19 patient enrolled in acute kidney injury drug trial
AM-Pharma has announced the enrolment and financing of a COVID-19 cohort in its Phase III acute kidney injury treatment trial.
